<DOC>
	<DOCNO>NCT01582932</DOCNO>
	<brief_summary>Calcipotriene vitamin D3 analog use topical therapy adult subject plaque-type psoriasis since 1993 . Calcipotriene foam , 0.005 % , approved 2010 treatment plaque psoriasis adult age 18 year old . The current study multicenter study compare calcipotriene foam , 0.005 % vehicle foam pediatric subject ( age 2 11 year , inclusive ) mild moderate plaque psoriasis . Subjects primary caregiver apply calcipotriene foam , 0.005 % , thin layer twice day body scalp 8 week . The safety , tolerability , pharmacodynamics , pharmacokinetics calcipotriene evaluate .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability Efficacy Calcipotriene Foam , 0.005 % , Versus Vehicle Foam Pediatric Subjects ( Ages 2-11 ) With Plaque Psoriasis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , Phase 3 study compare calcipotriene foam , 0.005 % , vehicle foam pediatric subject , age 2 11 year , inclusive , mild moderate plaque psoriasis . Subjects require plaque psoriasis affect least 5 % body surface area ( BSA ) involvement body least 5 % scalp involvement ( exclude face ) Investigator Static Global Assessment ( ISGA ) score mild moderate ( score 2 3 ) baseline . In addition , minimum 75 subject least 10 % BSA body ( exclude face scalp ) minimum 10 % scalp involvement ( exclude face ) ISGA score moderate . Subjects must target lesion &gt; 2 cm2 trunk extremity ( exclude palms/soles , knee , elbow , scalp , intertriginous area ) score 2 3 erythema , scaling , plaque thickness . Approximately 180 subject enrol dosed twice daily 8 week . Subjects randomly assign 1 2 treatment group 2:1 ratio ( calcipotriene foam , 0.005 % : vehicle foam ) . Study Duration , 2 week screen , 8 week treatment phone call Week 9 1 week early termination visit ( approximately 77 day total study ) . Blood sample evaluation albumin-adjusted serum calcium , intact PTH ( iPTH ) , alkaline phosphatase , magnesium , phosphorus collect screening , baseline ( predose ) , 1 9 hour application morning dose Weeks 2 8 visit . Blood sample collect dose baseline 1 9 hour dose Weeks 2 8 evaluation calcipotriene plasma concentration . Urine evaluation calcium/creatinine ratio collect baseline ( predose ) , 1 9 hour application morning dose Weeks 2 8 visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Male female subject , age 2 11 year , inclusive , time consent Clinical diagnosis mild moderate plaque psoriasis , define body ISGA score 2 3 scale 0 4 . Mild moderate plaque psoriasis involve least 5 % BSA least 5 % scalp involvement ( exclude face ) . Identification target lesion ( &gt; 2 cm2 ) trunk extremity score 2 3 0 5 scale erythema , scaling , plaque thickness Any inflammatory skin disease treatment area may confound evaluation plaque psoriasis Current diagnosis unstable form psoriasis treatment area , include guttate , erythrodermic , exfoliative , pustular psoriasis Use topical treatment know beneficial effect psoriasis , include limited corticosteroid , retinoids , vitamin D derivative , coal tar , tazarotene , medicate shampoo , anthralin , within 2 week prior enrollment Use nonbiologic systemic antipsoriatic therapy ( eg , corticosteroid , psoralen , retinoids , methotrexate , cyclosporine , immunosuppressive agent ) , biologic therapy ( eg , adalimumab , etanercept , golimumab , infliximab , ustekinumab ) , phototherapy ( eg , psoralen ultraviolet A [ PUVA ] , ultraviolet B [ UVB ] ) within 4 week prior enrollment Use need initiation nonpsoriatic therapy might affect psoriasis ( include antimalarial , Î²blockers , interferon , lithium ) within 4 week prior enrollment Use medication affect change calcium parathyroid hormone ( PTH ) concentration interfere measurement calcium PTH concentration within 4 week prior enrollment Known difficult venous access beyond expect subject age Average daily ingestion 2000 mg elemental calcium 1000 IU vitamin D within 2 week prior enrollment History hypersensitivity , know allergy , adverse reaction calcipotriene vitamin D analog component study product Current past history hypercalcemia , vitamin D toxicity , severe renal insufficiency , severe hepatic disorder Use investigational therapy within 4 week prior enrollment Pregnant breast feed female female use contraception Current immunosuppression Albuminadjusted serum calcium screen upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>plaque psoriasis</keyword>
</DOC>